"A Phase 3b Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Subjects on Chronic Hemodialysis [GS-US-292-1825]
Clinical Trial Grant
Administered By
Medicine, Infectious Diseases
Awarded By
Gilead Sciences, Inc.
Start Date
March 15, 2016
End Date
March 14, 2020
Administered By
Medicine, Infectious Diseases
Awarded By
Gilead Sciences, Inc.
Start Date
March 15, 2016
End Date
March 14, 2020